128 related articles for article (PubMed ID: 26296264)
1. Interleukin-6 as an emerging regulator of renal cell cancer.
Kamińska K; Czarnecka AM; Escudier B; Lian F; Szczylik C
Urol Oncol; 2015 Nov; 33(11):476-85. PubMed ID: 26296264
[TBL] [Abstract][Full Text] [Related]
2. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
Albiges L; Escudier B
Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
[TBL] [Abstract][Full Text] [Related]
4. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
5. Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.
Lee HW; Joo KM; Lim JE; Cho HJ; Cho HJ; Park MC; Seol HJ; Seo SI; Lee JI; Kim S; Jeong BC; Nam DH
Mol Cancer Res; 2013 Nov; 11(11):1375-86. PubMed ID: 23982215
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.
Tsimafeyeu I; Bratslavsky G
Oncology; 2015; 88(6):321-31. PubMed ID: 25678187
[TBL] [Abstract][Full Text] [Related]
7. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma.
Yao X; Qi L; Chen X; Du J; Zhang Z; Liu S
Urol Oncol; 2014 Feb; 32(2):162-70. PubMed ID: 23570708
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
10. Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.
Rodriguez AR; Fishman MN
Expert Opin Pharmacother; 2007 Dec; 8(17):2979-90. PubMed ID: 18001257
[TBL] [Abstract][Full Text] [Related]
11. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for sarcomatoid renal cell carcinoma.
Pagliaro LC; Tannir N; Sircar K; Jonasch E
Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
[TBL] [Abstract][Full Text] [Related]
14. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
15. Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.
Piva F; Giulietti M; Santoni M; Occhipinti G; Scarpelli M; Lopez-Beltran A; Cheng L; Principato G; Montironi R
Mol Diagn Ther; 2016 Apr; 20(2):111-7. PubMed ID: 26940073
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma bone metastasis--elucidating the molecular targets.
Weber K; Doucet M; Kominsky S
Cancer Metastasis Rev; 2007 Dec; 26(3-4):691-704. PubMed ID: 17768599
[TBL] [Abstract][Full Text] [Related]
17. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
18. New perspectives in the treatment of metastatic renal cell carcinoma.
Barrière J; Hoch B; Ferrero JM
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
[TBL] [Abstract][Full Text] [Related]
19. Renal cell cancer.
Hutson TE; Figlin RA
Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
[TBL] [Abstract][Full Text] [Related]
20. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
